A Phase 1b/2, Open-Label Trial To Assess The Safety And Preliminary Efficacy Of Epcoritamab (GEN3013; Duobody®-CD3xCD20) In Combination With Other Agents In Subjects With B-Cell Non-Hodgkin Lymphoma Read more
A Phase 1b/2, Open-Label, Safety And Efficacy Study Of Epcoritamab (GEN3013; Duobody®-CD3 X CD20) In Relapsed/Refractory Chronic Lymphocytic Leukemia Read more
A Phase II Study Of Venetoclax And Rituximab/Hyaluronidase Human In Relapsed/Refractory CLL Read more
A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Axicabtagene Ciloleucel In Combination With Either Rituximab Or Lenalidomide In Subjects With Refractory Large B-Cell Lymphoma (ZUMA-14) Read more
A Prospective, Open-Label, Multicenter Randomized Phase III Study To Compare The Efficacy And Safety Of A Combined Regimen Of Venetoclax And Obinutuzumab Versus Fludarabine, Cyclophosphamide, And Rituximab (FCR)/Bendamustine And Rituximab (BR) In FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL(17P) Or TP53 Mutation Read more
A Phase 2 Multicenter Study Evaluating The Efficacy Of KTE-C19 In Subjects With Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Read more
Extended Treatment Protocol For Subjects Continuing To Benefit From Ibrutinib After Completion Of Ibrutinib Clinical Trials Read more
